Department of Dermatology, Hôpital Henri-Mondor, 51, av du Maréchal de Lattre de Tassigny, FR-94010 Créteil Cedex, France. E-mail:
Acta Derm Venereol. 2021 Jun 22;101(6):adv00473. doi: 10.2340/00015555-3765.
Current management of moderate-to-severe psoriasis may be heterogeneous between European countries, probably due to differences in the organization of care. The aim of this study was to compare the utilization of systemic treatments for psoriasis between 2 coun-tries. All adults with psoriasis who were registered in the French (SNDS) and the Dutch (VEKTIS) national health insurance databases between 2012 and 2016 were eligible for inclusion. In France, 105,035 (15%) of 684,156 patients and, in the Netherlands, 37,405 (28.6%) of 130,822 patients received at least a systemic agent. In France, the proportion of patients treated with systemic agents was constant, while the type of drugs dispensed shifted from non-biological to biological agents. In the Netherlands, the first systemic treatment was methotrexate and, in France, acitretin. In France, the choice of the first biologic was much more variable than it was in the Netherlands, where a large proportion of patients were dispensed ustekinumab. This study highlights discrepancies between France and the Netherlands concerning the choice of first non-biologic agent and first biologic agent for patients with psoriasis. These discrepancies may be due to differences in the healthcare systems between the 2 countries.
目前，欧洲国家之间中重度银屑病的治疗方法可能存在差异，这可能是由于护理组织的差异造成的。本研究旨在比较 2 个国家之间银屑病系统治疗的应用情况。在 2012 年至 2016 年间，法国（SNDS）和荷兰（VEKTIS）国家健康保险数据库中登记的所有成年银屑病患者都符合纳入标准。在法国，有 105035 名（15%）患者和荷兰 37405 名（28.6%）患者至少接受了一种全身药物治疗。在法国，接受全身药物治疗的患者比例保持不变，而所开药物的类型从非生物制剂转向生物制剂。在荷兰，首选的第一种系统治疗药物是甲氨蝶呤，而在法国则是阿维 A 酯。在法国，选择第一种生物制剂的种类比荷兰更为多样化，荷兰有很大一部分患者使用乌司奴单抗。本研究强调了法国和荷兰在银屑病患者首选非生物制剂和首选生物制剂方面的差异。这些差异可能是由于两国医疗保健系统的差异造成的。
